However, the biomarkers that predict the efficacy of ICIs therapy, including programmed death protein legend 1(PD-L1), mismatch repair deficiency, and tumor mutation burden (TMB), are still unsatisfactory in identifying the whole beneficiaries (Jin et al., 2022). This evidence concerns the gene CD274 and neoplasm.